Socrates E. Papapoulos

Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research

Elizabeth Shane, David B. Burr, Peter R. Ebeling et al. · Journal of Bone and Mineral Research · 2010 · 1.1K citations

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

Kenneth Poole, Rutger L. van Bezooijen, N. Loveridge et al. · The FASEB Journal · 2005 · 954 citations

Adult Iliac Bone, Sclerostin, Bone Formation +16

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

Henry G. Bone, Rachel B. Wagman, Maria Luisa Brandi et al. · The Lancet Diabetes & Endocrinology · 2017 · 916 citations · Full text

Bone Disease, Denosumab Treatment, Bone Health +9

Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist

Rutger L. van Bezooijen, Bernard A.J. Roelen, Annemieke Visser et al. · The Journal of Experimental Medicine · 2004 · 876 citations · Full text

Sclerostin, Bone Surface, Immunology +21

Interim Report and Recommendations of the World Health Organization Task-Force for Osteoporosis

Harry K. Genant, Cyrus Cooper, Gyula Poór et al. · Osteoporosis International · 1999 · 782 citations

Bone Disease, Bone Health, Health Policy +7